Last:
Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

Syndax is a clinical stage biopharmaceutical company focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Their lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from their Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer.